Tetraphase Pharmaceuticals Inc. (TTPH)

4.69
0.38 7.50
NASDAQ : Health Technology
Prev Close 5.07
Open 5.07
Day Low/High 4.58 / 5.37
52 Wk Low/High 3.36 / 49.60
Volume 106.27K
Avg Volume 462.40K
Exchange NASDAQ
Shares Outstanding 2.72M
Market Cap 12.76M
EPS -27.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Tetraphase Pharmaceuticals Announces Proposed Offering Of Common Stock

Tetraphase Pharmaceuticals Announces Proposed Offering Of Common Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced it has commenced an underwritten public offering of 3,300,000 shares of its common stock.

3 Antibiotic Stocks Targeting Most Urgent Bacterial Threats

3 Antibiotic Stocks Targeting Most Urgent Bacterial Threats

Cubist, Cempra and Tetraphase are all developing antibiotics to combat a new wave of scary bacterial superbugs.

Tetraphase To Present New Data At IDWeek On Eravacycline’s Potential Activity In Treating Serious Respiratory Infections

Tetraphase To Present New Data At IDWeek On Eravacycline’s Potential Activity In Treating Serious Respiratory Infections

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it will present two posters at IDWeek 2013 that examine the potential of its lead antibiotic candidate, eravacycline, to treat serious...

Tetraphase Outlines Plans For Phase 3 Clinical Trial Of Eravacycline IV/oral In Complicated Urinary Tract Infections

Tetraphase Outlines Plans For Phase 3 Clinical Trial Of Eravacycline IV/oral In Complicated Urinary Tract Infections

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), today announced the design of its planned Phase 3 IV/oral clinical trial of the Company’s lead antibiotic candidate eravacycline in the treatment of complicated ...

4 Biotech Stocks Triggering Breakout Trades

4 Biotech Stocks Triggering Breakout Trades

Keep thees biotech stocks trading on unusual volume on your radar.

Tetraphase Pharmaceuticals To Present At Upcoming Conferences

Tetraphase Pharmaceuticals To Present At Upcoming Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria...

Tetraphase Doses First Patient In Phase 3 Clinical Trial Of Eravacycline In Complicated Intra-abdominal Infections

Tetraphase Doses First Patient In Phase 3 Clinical Trial Of Eravacycline In Complicated Intra-abdominal Infections

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the dosing of the first patient in its Phase 3 clinical trial of its lead drug candidate eravacycline for the treatment of complicated intra-abdominal ...

Tetraphase Reports Second Quarter 2013 Financial Results

Tetraphase Reports Second Quarter 2013 Financial Results

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter ended June 30, 2013.

Tetraphase: Another Good Investment In Hot Antibiotic Market

Tetraphase: Another Good Investment In Hot Antibiotic Market

The company's antibiotic won't have late-stage study data available until 2015 but it's worth the wait.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

FDA Grants QIDP Designation To Eravacycline, Tetraphase’s Lead Antibiotic Product Candidate

FDA Grants QIDP Designation To Eravacycline, Tetraphase’s Lead Antibiotic Product Candidate

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) today announced that the U.

Small-Cap Biotechs Pursue IPOs Fastest in Decade

Small-Cap Biotechs Pursue IPOs Fastest in Decade

The bar for progress has been lowered for biotechs looking to enter the market.

Top Insider Trades: TTPH PRTS APA FB

Top Insider Trades: TTPH PRTS APA FB

The top 10 open-market insider purchases and sales filed at the SEC Wednesday.

Medical IPOs - Are They Healthy?

Medical IPOs - Are They Healthy?

IPO Desktop President Francis Gaskins and TheStreet's Debra Borchardt look at the Enanta Pharmaceuticals and Tetraphase Pharmaceuticals offerings.

TheStreet Quant Rating: D- (Sell)